Clinical Trial Update: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating durvalumab with local consolidative therapy for oligoprogressive and polyprogressive stage III non-small cell lung cancer af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7 | Phase 2 | Status: RECRUITING